CN110003129B - 一种佐米曲普坦中间体的制备方法 - Google Patents
一种佐米曲普坦中间体的制备方法 Download PDFInfo
- Publication number
- CN110003129B CN110003129B CN201910311606.XA CN201910311606A CN110003129B CN 110003129 B CN110003129 B CN 110003129B CN 201910311606 A CN201910311606 A CN 201910311606A CN 110003129 B CN110003129 B CN 110003129B
- Authority
- CN
- China
- Prior art keywords
- oxazolidinone
- nitrobenzyl
- ammonium formate
- percent
- palladium carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 title claims abstract description 26
- 229960001360 zolmitriptan Drugs 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims abstract description 46
- CCEJPIYBVGYGEM-QMMMGPOBSA-N (4s)-4-[(4-nitrophenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1C[C@@H]1NC(=O)OC1 CCEJPIYBVGYGEM-QMMMGPOBSA-N 0.000 claims abstract description 42
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 claims abstract description 31
- 238000006243 chemical reaction Methods 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 22
- WNAVSKJKDPLWBD-VIFPVBQESA-N (4s)-4-[(4-aminophenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(N)=CC=C1C[C@@H]1NC(=O)OC1 WNAVSKJKDPLWBD-VIFPVBQESA-N 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 18
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000013078 crystal Substances 0.000 claims description 9
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 abstract description 8
- 230000009467 reduction Effects 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 2
- -1 (S) -4- (4-nitrobenzyl) -2-oxazolidinone ammonium formate Chemical compound 0.000 description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000852 hydrogen donor Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 210000003363 arteriovenous anastomosis Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940044631 ferric chloride hexahydrate Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910311606.XA CN110003129B (zh) | 2019-04-18 | 2019-04-18 | 一种佐米曲普坦中间体的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910311606.XA CN110003129B (zh) | 2019-04-18 | 2019-04-18 | 一种佐米曲普坦中间体的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110003129A CN110003129A (zh) | 2019-07-12 |
CN110003129B true CN110003129B (zh) | 2021-04-06 |
Family
ID=67172725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910311606.XA Active CN110003129B (zh) | 2019-04-18 | 2019-04-18 | 一种佐米曲普坦中间体的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110003129B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115097023B (zh) * | 2022-05-31 | 2023-07-25 | 山东泰合医药科技有限公司 | 佐米胺有关物质的高效液相色谱检测方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY30121A1 (es) * | 2006-02-03 | 2007-08-31 | Glaxo Group Ltd | Nuevos compuestos |
CN101289430A (zh) * | 2008-06-06 | 2008-10-22 | 广东肇庆星湖生物科技股份有限公司 | 药物中间体(s)-4-(4-氨基苄基)-2-噁唑烷酮的合成新方法 |
CN102199146A (zh) * | 2010-03-22 | 2011-09-28 | 上海希迪制药有限公司 | 制备n-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺的方法 |
CN103275075B (zh) * | 2013-06-24 | 2015-01-07 | 成都天台山制药有限公司 | 佐米曲普坦及其制备方法 |
-
2019
- 2019-04-18 CN CN201910311606.XA patent/CN110003129B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110003129A (zh) | 2019-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1856024A1 (de) | Verfahren zur herstellung substituierter biphenyle | |
CN113214133B (zh) | 一种褪黑素的合成方法 | |
CN106164052A (zh) | 用于制备恩杂鲁胺的方法 | |
CN110003129B (zh) | 一种佐米曲普坦中间体的制备方法 | |
SU509232A3 (ru) | Способ получени производныхоксадиазолина | |
US2683173A (en) | Amide preparation | |
CN104402795B (zh) | 取代吲哚‑2‑甲酸的合成方法 | |
CN101747284A (zh) | 一种抗氧剂的制备方法 | |
CN105924404B (zh) | 一种紫外线吸收剂uv-p的制备方法 | |
US3123615A (en) | Oxyphenyl | |
CN111732544B (zh) | 一种合成3-(4-甲基-1h-咪唑-1-基)-5-(三氟甲基)苯胺的方法 | |
CN109053623B (zh) | 一种4-甲基-5-噻唑甲醛的制备方法 | |
CN103044272A (zh) | 一种4-亚硝基-n-乙基-n-羟乙基苯胺的制备方法 | |
CN111269144A (zh) | 一种氨基苯甲腈的制备方法 | |
CN106243010A (zh) | 一种4‑硝基吲哚的制备方法 | |
CN111393382A (zh) | 一种1-乙酸四氮唑的制备方法 | |
CN114573555A (zh) | 一种用于治疗偏头痛的化合物的制备方法 | |
CN106008376B (zh) | 一种紫外线吸收剂uv-329的制备方法 | |
CN105884702B (zh) | 一种紫外线吸收剂uv-234的制备方法 | |
CN110143881B (zh) | 选择性还原不同链长的化合物、特别是啶酰菌胺中间体合成母液中硝基化合物的方法 | |
CN112300151B (zh) | 一种马罗匹坦中间体的制备方法 | |
CN109020838B (zh) | 一种肼基甲酸酯的制备方法 | |
CN116987018A (zh) | 一种喹硫平中间体的制备方法 | |
WO2007133040A1 (en) | Method for preparing losartan | |
JPH09124605A (ja) | 3,4−ジヒドロカルボスチリルの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method of zolmitriptan intermediate Effective date of registration: 20220113 Granted publication date: 20210406 Pledgee: Jinan area branch of Shandong free trade zone of Qilu Bank Co.,Ltd. Pledgor: JINAN LEAD PHARM-CHEMICAL Co.,Ltd. Registration number: Y2022370000013 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231115 Granted publication date: 20210406 Pledgee: Jinan area branch of Shandong free trade zone of Qilu Bank Co.,Ltd. Pledgor: JINAN LEAD PHARM-CHEMICAL Co.,Ltd. Registration number: Y2022370000013 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method for the intermediate of zomitriptan Effective date of registration: 20231207 Granted publication date: 20210406 Pledgee: Bank of Beijing Co.,Ltd. Jinan Branch Pledgor: JINAN LEAD PHARM-CHEMICAL Co.,Ltd. Registration number: Y2023980069811 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231220 Granted publication date: 20210406 Pledgee: Bank of Beijing Co.,Ltd. Jinan Branch Pledgor: JINAN LEAD PHARM-CHEMICAL Co.,Ltd. Registration number: Y2023980069811 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A preparation method for the intermediate of zomitriptan Effective date of registration: 20240103 Granted publication date: 20210406 Pledgee: Bank of Beijing Co.,Ltd. Jinan Branch Pledgor: JINAN LEAD PHARM-CHEMICAL Co.,Ltd. Registration number: Y2023370000139 |